SMN2 and proximal spinal muscular atrophy: Nusinersen, which specifically modifies SMN2 splicing, has been approved for the treatment of all SMA subtypes based on two double-blind, sham-controlled, phase 3 studies conducted in infants and children up to nine years of age at the time of enrollment into the trial [7, 8].